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ABSTRACT 
Uveitis is defined as intraocular inflammation. It is an extra-articular manifestation of many forms of 
joint disease which include spondyloarthritis, juvenile idiopathic arthritis, and Behcet’s disease.  
Rheumatologists may be asked to consult on patients with uveitis in order to identify an associated 
systemic illness. Diagnoses such as spndyloarthritis, sarcoidosis, and interstitial nephritis with uveitis 
are frequently overlooked by referring ophthalmologists. Alternatively rheumatologists may be 
asked to help manage the immunosuppression including biologics which can be required to treat a 
subset of patients with uveitis. This review is written to provide rheumatologists with the necessary 
information to facilitate collaboration in co-managing patients with uveitis. 
 
Imagine a symphony orchestra in which the conductor cannot coordinate the play of the wind 
instruments with the strings or percussion. Imagine a basketball or soccer team that has not 
mastered the concept of passing the ball. Imagine an epidemiologic study in which the statisticians 
and those who conceptualized the study, each have different understandings of the study’s purpose. 
Many endeavors represent a gestalt for which the anticipated goal requires multiple parts; and the 
whole is greater than the sum of those parts. Since rheumatologists see patients with multi-system 
disease, they are well aware of this need for collaboration. Uveitis, also known as intraocular 
inflammation, is a prototypical illness that begs for collaboration. Uveitis is often best assessed and 
optimally treated by an inter-disciplinary team. In this review, we seek to prepare rheumatologists 
with information that can facilitate the success of this collaborative effort. 
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BACKGROUND 
The term, uvea, derives from the Latin word for grape. The Roman anatomists felt that peeling away 
the outer layer of the eye, the cornea and sclera, left a grape-like structure: the iris, ciliary body, and 
choroid (see Figure 1). Any portion of the uvea can be inflamed and often the inflammation involves 
adjacent structures (see Figure 2). So anatomic subsets of uveitis include iritis (synonymous with 
anterior uveitis), iridocyclitis, intermediate uveitis,  posterior uveitis (such as choroiditis, 
retinochoroiditis, chorioretinitis), and panuveitis. Just as increased leukocytes in synovial fluid are 
indicative of synovitis, so leukocytes in either the aqueous humor or vitreous humor are taken as 
evidence of uveitis, even though neither the anterior chamber that is filled with aqueous humor nor 
the vitreous cavity is technically a part of the uveal tract. 
Uveitis has a prevalence of roughly one per thousand 1. Several forms of uveitis are episodic and the 
prevalence is usually stated as a point prevalence meaning that active disease was present at the 
time of the survey. Despite its relative rarity, uveitis accounts for approximately the same amount of 
visual morbidity as either macular degeneration or diabetic retinopathy 2, although the latter two 
diseases are generally more commonly recognized by the public as major causes of visual loss. The 
duration of some subsets of uveitis probably accounts for this paradox. Both macular degeneration 
and diabetic retinopathy are diseases that occur toward the end of life. In contrast, uveitis might 
start in childhood or early adulthood and persist through decades. 
THE UVEITIS-RHEUMATOLOGY INTERFACE 
Patients with uveitis often do need a rheumatologist. As shown in Table I, many systemic, rheumatic 
diseases can involve both the joints and the uveal tract. Furthermore, most forms of uveitis are 
immune-mediated and respond to immune suppression, a type of therapy that is outside the 
expertise of most ophthalmologists. 
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Just as arthritis has multiple causes, so uveitis has multiple etiologies. Broad etiologic categories are 
provided in Table 2. The majority of patients with uveitis have an immune-mediated process. This is 
supported by observation of leukocytes in the eye and by the known ability to produce uveitis in 
laboratory animals by stimulating the immune response. But just as systemic lupus and rheumatoid 
arthritis differ in the preferred approach to therapy even though both are immune-mediated, so it is 
likely that the preferred treatment for a form of uveitis, such as that secondary to juvenile idiopathic 
arthritis, will differ from the optimal therapy for another form of uveitis such as that secondary to 
sarcoidosis. Currently, however, most therapy for non-infectious uveitis is determined more by the 
severity and the anatomic location rather than the etiology, although some notable exceptions are 
slowly emerging. 
Although case reports rarely elucidate pathogenesis, the course of a physician who survived Ebola 
infection may reveal clues about the intersection between uveitis and rheumatic diseases 3. The 
patient contracted Ebola in Africa and was flown to Atlanta for care. Although he experienced multi-
organ failure, he survived. Fourteen weeks after presentation, he had a severe uveitis and the Ebola 
virus could be recovered from his eye, presumably because the eye is an immune-privileged site. The 
virus was no longer detectable in blood. At the time that the uveitis developed, he also had low back 
pain and enthesitis, symptoms suggestive of a spondyloarthropathy, although the uveitis was 
intermediate and posterior, locations which are not typically inflamed with ankylosing spondylitis. 
For joint swelling, we narrow the differential diagnosis based on parameters such as which joints are 
involved, whether the disease is symmetric or asymmetric, whether the onset was acute or 
insidious, and the patient’s age and gender. Similarly, uveitis subsets are recognized by such 
variables as the anatomic portion of the uveal tract which is inflamed, by whether the disease is 
unilateral or bilateral, by whether the inflammation is chronic or episodic, by whether the onset 
began suddenly or insidiously, and of course, by the patient’s age and gender. Both Behcet’s disease 
and ankylosing spondylitis, for example, are associated with uveitis. Both Behcet’s disease and 
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ankylosing spondylitis might be associated with low back pain, peripheral arthritis and diarrhea. Oral 
sores are often present in HLA B27-associated reactive arthritis, just as they are present in Behcet’s 
disease. But the uveitis associated with ankylosing spondylitis almost always affects only one eye at 
a time, lasts no longer than 3 months, predominantly affects the anterior uveal tract, may cause 
hypopyon (pus in the anterior chamber of the eye; see Table 3 for a glossary of relevant terms), and 
tends to be recurrent 4. The uveitis associated with Behcet’s disease is also recurrent but rarely is the 
eye completely uninflamed between attacks.  The uveitis associated with Behcet’s disease is usually 
bilateral. It is usually both an anterior and intermediate uveitis (intermediate uveitis is recognized by 
leukocytes in the vitreous humor) or a panuveitis, often with retinal vasculitis. While both diseases 
cause hypopyon, the eye of a patient with ankylosing spondylitis and hypopyon is red, tender, and 
sensitive to light; fibrin is frequently present in the anterior chamber. In contrast, hypopyon in 
association with Behcet’s disease need not cause pain or redness. Fibrin is rarely present. In some 
instances, history alone can help distinguish the two entities since history will usually help determine 
if one or both eyes are affected or the duration of the eye inflammation. But other subtleties, such 
as the presence of retinal vasculitis, require a specialist eye examination to detect. Thus, the 
ophthalmologist potentially can help the rheumatologist make a diagnosis and the rheumatologist 
can assist the ophthalmologist in differential diagnosis of the systemic disease and collaborate with 
the management of immunosuppression. 
The co-existence of uveitis and arthritis is also not well understood despite how frequently this 
occurs as is shown in Table 1. Some specific forms of uveitis are discussed in Table 4. Both the eye 
and joint do share some biochemical similarities such as the presence of hyaluronic acid, type II 
collagen, and aggrecan. Uveitis and arthritis also occur together in several animal models such as the 
SKG mouse 5, adjuvant arthritis in rats 6, and aggrecan-induced arthritis in BALB/C mice 7. The co-
existence suggests a shared pathogenesis, but in the aggrecan model, mice which do not produce 
gamma interferon develop far more severe uveitis, while the arthritis is dramatically ameliorated 7. 
Similarly characterizing the genetics of the uveitis associated with HLA B27 shows that ankylosing 
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spondylitis and acute anterior uveitis share a variety of predisposing genes such as HLA B27 itself, 
the IL-23 receptor, and ERAP-1. At the same time, there are identifiable genes such as IL-6R, 
probably IL-10, and IL-18R1 that seem to influence solely the susceptibility to acute anterior uveitis 8. 
 
DIFFERENTIAL DIAGNOSIS AND LABORATORY TESTING 
The heterogeneity of uveitis has multiple implications. In terms of differential diagnosis, it is 
obviously critical to distinguish an infection from an immune-mediated cause of uveitis. Some 
infections, such as syphilis and tuberculosis, can be quite variable in terms of their presentation 
within the eye and frequently enter into the differential diagnosis. Some of the more common 
infectious causes of uveitis include herpes simplex, herpes zoster, toxoplasmosis, and 
cytomegalovirus (the latter usually in an immunocompromised host). Most infections of the uveal 
tract cause characteristic changes that can be recognized with a slit lamp examination or with 
indirect ophthalmoscopy. The “partnership” between a rheumatologist and ophthalmologist, in our 
opinion, is such that the rheumatologist must trust that the ophthalmologist has excluded an 
infection; both specialists must be aware that a patient who fails to respond to immunosuppression 
could have an overlooked infectious cause for her disease. Likewise, two other etiologies, 
masquerade syndromes and drug-induced disease, are relatively rare, but each has distinct 
therapeutic implications. The most common uveitis “masquerade” is probably a B cell lymphoma 
that is usually confined to the brain and the eye 9, 10. It typically occurs bilaterally in patients who are 
over 45. This diagnosis can easily be missed. Medications do not usually cause uveitis, but possible 
culprits include iv bisphosphonates 11, TNF inhibitors 12, checkpoint inhibitors 13 and several 
antibiotics 14.  
In rheumatology, distinguishing gout from rheumatoid arthritis as a cause of joint swelling will 
markedly change the therapeutic strategy. Most forms of non-infectious uveitis are approached by a 
treatment algorithm that is not impacted by the cause of the uveitis. Two prominent exceptions are 
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Behcet’s disease and the anterior uveitis associated with juvenile idiopathic arthritis. For Behcet’s 
disease, a monoclonal antibody that inhibits TNF is used frequently because of the dramatic efficacy 
15. For the anterior uveitis associated with JIA, the more frequent use of methotrexate and/or a TNF 
inhibitor such as adalimumab has improved the prognosis for this disease markedly 16. 
The above considerations regarding differential diagnosis obviously impact the search for an 
etiology. The rheumatologist is often tasked with finding a systemic, immune-mediated cause, but 
should not be the practitioner who diagnoses an infection or masquerading malignancy as a cause. 
As is true of differential diagnosis in general, the history is key and pattern recognition aids greatly in 
the goal. Some forms of uveitis such as Behcet’s disease or Vogt-Koyanagi-Harada (VKH) syndrome 
are clinical diagnoses without a definitive laboratory test. Other diagnoses, like Crohn’s disease, 
ulcerative colitis, or sarcoidosis, can be established or supported by biopsy or imaging, but the 
procedure may be too costly, too toxic (radiation from a CT scan of a young person), too unlikely to 
yield positive results, or too uncomfortable (colonoscopy) to recommend on a routine basis. Our 
practice is to choose tests selectively based on clues gained from the examination or history. For 
example, multiple areas of serous elevation of the retina can be detected on examination and 
confirmed by testing such as optical coherence tomography or fluorescein angiography. The finding 
suggests a diagnosis of VKH.  
The most common systemic disease associated with uveitis is spondyloarthritis. Roughly half of all 
patients with sudden onset, non-infectious, anterior uveitis in Europe or North America are HLA B27 
positive 17. Recent studies, one from an emergency room in Dublin, Ireland 18 and another from 
Spain involving 798 subjects and a collaboration between rheumatologists and ophthalmologists 19, 
concluded that roughly 80% of patients with B27-associated acute anterior uveitis have axial 
spondyloarthritis based on ASAS criteria. This observation held although both studies excluded any 
patient with uveitis who had a known spondyloarthropathy. Spondyloarthritis is less common among 
those who have anterior uveitis and are HLA B27 negative, but the diagnosis remains surprisingly 
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frequent 19. Older studies using more stringent criteria to diagnose spondyloarthritis had also 
concluded that spondyloarthropathy was endemic among patients with anterior uveitis 4, 20. 
Rheumatologists who are unaware of this association will frequently fail to recognize the clinical 
significance of the chronic inflammatory back pain that afflicts many with anterior uveitis. 
Another critical cause of uveitis to appreciate is sarcoidosis. In a study from the Cleveland Clinic, 57% 
of women over 61 years of age with idiopathic uveitis had normal chest x-rays but chest CT evidence 
for sarcoidosis 21. We have recently found a similar, slightly lower yield by performing chest CTs on 
patients with idiopathic uveitis over 40 years of age 22. In addition, we noted that 21% of those 
discovered to have sarcoidosis on chest CT also had cardiac sarcoidosis with associated ventricular 
tachycardia 22. Thus, recognition of the systemic illness had potentially life-saving implications. A 
study from Japan reached a similar conclusion about uveitis and cardiac sarcoidosis 23. 
While most systemic rheumatic diseases associated with uveitis such as Behçet’s disease are 
diagnosed on the basis of the clinical presentation, tubulointerstitial nephritis with uveitis (TINU) is 
another of those easily overlooked entities. Rheumatologists might be asked to see a patient with 
TINU because the patient has bilateral red eyes and photophobia from the anterior uveitis and the 
patient is typically systemically ill with fever, myalgias, a markedly elevated erythrocyte 
sedimentation rate, mild anemia, and mildly abnormal liver enzymes 24, 25. Unless one is cognizant of 
the diagnosis and requests a measurement of beta2 microglobulin in the urine, the diagnosis is 
frequently overlooked. 
In virtually every series of patients with uveitis, a diagnosis of “idiopathic” disease is the most 
common etiology noted 26. Other terms to describe idiopathic uveitis include non-classifiable, 
primary uveitis or undifferentiated disease 27. 
Despite the breadth of the differential diagnosis for uveitis, the rheumatologist should be able to 
take a relatively targeted approach to laboratory testing 28. The examination by the ophthalmologist 
should have identified any suspicion for a masquerade syndrome or an infectious cause. The detailed 
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history should point to most of the possible associated systemic, immune-mediated diseases. If 
history and exam have failed to point to a probable cause, we screen for syphilis since this infection 
can be latent for many years and its uveal manifestations are protean. In addition, we obtain a chest 
x-ray as sarcoidosis might be asymptomatic in the lungs and this is also useful as a screen for 
tuberculosis. The sensitivity for either ocular tuberculosis or sarcoidosis using chest x-ray is probably 
50% or worse.  Because of the extensive radiation, we usually do not obtain a chest CT scan to 
search for sarcoid unless the patient is over 40 years of age 22. In the US, we also do not screen for 
tuberculosis exposure unless the patient has a specific risk factor for tuberculosis such as birth 
outside the United States or a history of incarceration 29. Additional tests might be useful to monitor 
therapy such as a complete blood count and metabolic panel. Targeted testing is also useful if the 
presentation suggests a specific entity. For example, we often test for HLA B27 if the patient 
presents with unilateral, acute, anterior uveitis. We check urine for beta 2 microglobulin for patients 
who present with a bilateral, sudden onset, anterior uveitis. We consider multiple sclerosis if the 
patient relates neurological symptoms that might be explained by this diagnosis. 
THERAPY 
The heterogeneity of uveitis has impacted the ability to design clinical trials. The relative rarity of 
vision threatening uveitis is such that different etiologies are usually combined into one clinical trial. 
However, the manifestations of a disease such as birdshot retinochoroidopathy are such that the 
endpoint for treating it differ greatly from the endpoint in treating an inflammation such as Behcet’s 
disease. This challenge in trial design may have contributed to the failure of promising therapies 
such as voclosporine (a congener of cyclosporine), secukinumab (anti IL-17A) 30, 31, gevokizumab (anti 
IL-1 beta) 32or intravitreal rapamycin 33 to show consistent benefit in clinical uveitis trials. 
Most practitioners treat uveitis initially, especially anterior uveitis, with topical corticosteroids. 
Although these are frequently effective, their penetration posterior to the lens is limited. In addition, 
use of topical corticosteroids can be complicated by cataractogenesis or elevated intraocular 
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pressure. One formulation, difluprednate, has greater ability to treat inflammation posterior to the 
lens, but it also has a greater tendency to cause a cataract or glaucoma. If topical corticosteroids fail, 
a locally injected corticosteroid such as triamcinolone can be useful. However, in addition to being 
an uncomfortable injection, risks include cataract, glaucoma, lid ptosis, and rarely retinal 
detachment. Triamcinolone can be injected directly into the vitreous humor where it has increased 
benefit and increased risk of intraocular infection or hemorrhage. Oral corticosteroids represent an 
additional option, but long-term use has toxicity well known to rheumatologists 34. Antimetabolites 
including mycophenolate mofetil, methotrexate, and azathioprine are popular corticosteroid-steroid 
sparing drugs used by uveitis experts 35. Additional options include calcineurin antagonists such as 
cyclosporine or tacrolimus 36, alkylators like cyclophosphamide, or long-lasting corticosteroid 
implants delivered either by surgery or injection. 
The rheumatologist has a major role to play in managing the therapy of a subset of patients with 
ocular inflammatory disease.  Many ophthalmologists are comfortable prescribing oral 
corticosteroids but rarely resort to steroid sparing medications 37. The dosage of prednisone or its 
equivalent is often such that the treatment has considerable morbidity. An NIH sponsored trial 
known as MUST (Multicenter Uveitis Steroid Trial) for patients with non-infectious, intermediate, 
posterior or panuveitis recently showed superior efficacy for systemic immunosuppression as with 
anti-metabolites compared to a sustained release of fluocinolone into the vitreous humor of the eye. 
This conclusion was based on visual acuity with 7 years of follow-up 383. 
Progress in approval of new therapies for uveitis is hampered by the relative rarity of specific forms 
of uveitis, by the variety of presumed causes, and by the heterogeneity of outcomes that might 
define successful therapy. In two time to treatment failure trials reported in 2016, adalimumab 
showed clear-cut benefit for non-infectious intermediate, posterior or panuveitis 39, 40. In most 
instances, adalimumab is indicated for patients who have failed therapy with oral corticosteroids as 
well as another oral immunosuppressant such as methotrexate or mycophenolate mofetil. The 
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responsiveness of Behcet’s disease to adalimumab or infliximab is such that the authors’ sometimes 
consider such therapy without a trial of an anti-metabolite 41. Multiple sclerosis (MS) can be 
associated with intermediate uveitis 42. As MS is a relative contraindication to inhibiting TNF, this 
diagnosis may need to be excluded prior to starting adalimumab therapy for uveitis.  
It is rare to prescribe a biologic for anterior uveitis, since most patients with anterior uveitis can be 
controlled with topical medication alone. An exception is the uveitis characteristically associated 
with one subset of patients with juvenile idiopathic arthritis (JIA). The typical JIA patient with chronic 
uveitis has disease that begins between the ages of two and eight and affects a few joints. The 
majority have a positive ANA and are female. The SYCAMORE study tested the efficacy of 
adalimumab for patients with JIA whose uveitis was active despite methotrexate and topical 
corticosteroids 43. The trial was halted early since the evidence for benefit was apparent. Another 
randomized controlled trial used a different outcome measure, quantification of protein in the 
anterior chamber of the eye, and also concluded that adalimumab was useful for the chronic 
anterior uveitis associated with JIA 44.  
These successes have encouraged additional uveitis trials such as one assessing the benefit of the Jak 
inhibitor, filgotinib, for indications similar to those supporting the use of adalimumab. Many 
emerging biologics, however, have not been studied rigorously for possible benefit in the treatment 
of uveitis. And while uveitis is increasingly targeted in therapeutic trials, a search of the website, 
clinicaltrials.gov in February, 2018, identified only 7 current or prior randomized controlled trials for 
uveitis.  A similar search for rheumatoid arthritis identified 54 trials. Finally, although some 
ophthalmologists are comfortable prescribing immunosuppression without close physician 
collaboration, virtually all ophthalmologists lack an infrastructure that is prepared to deal with the 
systemic infectious complications which are rare but unavoidable when one suppresses the immune 
system. 
To aid physicians who care for patients with uveitis, several international groups have recently 
offered guidelines to assist in the care of patients with ocular inflammatory diseases 45, 46. The FOCUS 
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(Fundamentals of Care for Uveitis) group consisted of 146 international experts who graded the 
strength of the evidence and who used consensus methodology. 45 
Patients with spondyloarthritis tend to have recurrent episodes of uveitis. As most of these episodes 
are anterior, last for no more than 3 months, and can be managed with topical corticosteroids alone, 
the issue of prophylaxis often does not arise. Several medications do reduce the frequency of uveitis. 
The use of sulfasalazine to prevent attacks of uveitis in patients with spondyloarthritis is supported 
by randomized controlled trials 47, 48. Monoclonal antibodies that neutralize TNF, especially 
adalimumab or infliximab, also prevent attacks of uveitis 49, but these are not generally prescribed if 
the sole reason is to prevent attacks of anterior uveitis. At this time, extensive data on how 
treatments such as secukinumab or tofacitinib affect recurrent uveitis in patients with spondylitis 
have not been published. 
In the future, therapies delivered locally to the eye might become the treatment of choice for ocular 
inflammation. Locally injected corticosteroid into the eye itself can be very effective, but the therapy 
is limited, in part because the medication frequently causes cataract and glaucoma. Gene therapy 
for inherited retinal degeneration has now been FDA approved and is successful in part because the 
injected gene enters a confined space with minimal worries about expression in other tissues 50. In 
contrast to polyarticular rheumatoid arthritis, successful gene therapy for ocular inflammation needs 
to target no more than two locations. In the decades ahead, one or more locally delivered inhibitors 
of inflammation might become standard of care for uveitis. 
CONCLUSION: 
We recognize the challenges to familiarize oneself with a group of diseases which one cannot fully 
assess by using the tools in a conventional rheumatology clinic. And we empathize with the time 
requirements that impair optimal management of a patient whose illness requires two or more 
subspecialists to confer.  Mechanisms that facilitate communication with an ophthalmologist include 
interdisciplinary clinics and case conferences to discuss patients whose illness lies in the interstices 
between these two disciplines.  The gratification of practicing medicine derives primarily from the 
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opportunity to improve the welfare of our patients. That welfare is best served if we as 
rheumatologists share our knowledge and experience, while welcoming the collaboration of 
ophthalmologists who quite literally have a different view of our patients and their disease. Just as a 
conductor of a symphony orchestra coordinates multiple musicians, physicians can and should 
achieve a similar collaboration. 
 
1. Thorne JE, Suhler E, Skup M, Tari S, Macaulay D, Chao J, et al. Prevalence of Noninfectious 
Uveitis in the United States: A Claims-Based Analysis. JAMA Ophthalmol. 2016;134:1237-45. 
2. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14:303-8. 
3. Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, Mehta AK, et al. Persistence of Ebola 
Virus in Ocular Fluid during Convalescence. N Engl J Med. 2015;372:2423-7. 
4. Rosenbaum JT. Characterization of uveitis associated with spondyloarthritis. J Rheumatol. 
1989;16:792-6. 
5. Ruutu M, Thomas G, Steck R, Degli-Esposti MA, Zinkernagel MS, Alexander K, et al. beta-
glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice. Arthritis Rheum. 
2012;64:2211-22. 
6. Petty RE, Johnston W, McCormick AQ, Hunt DWC, Rootman J, Rollins DF. Uveitis and arthritis 
induced by adjuvant: Clinical, immunologic and histologic characteristics. J Rheumatol. 1989;16:499-
505. 
7. Kezic JM, Davey MP, Glant TT, Rosenbaum JT, Rosenzweig HL. IFN-gamma regulates 
discordant mechanisms of uveitis versus joint and axial disease in a murine model resembling 
spondyloarthritis. Arthritis Rheum. 2011;64:762-71. 
8. Robinson PC, Claushuis TA, Cortes A, Martin TM, Evans DM, Leo P, et al. Genetic dissection 
of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing 
spondylitis. Arthritis Rheumatol. 2015;67:140-51. 
9. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT. Expression of B-cell-
attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary 
central nervous system lymphoma. Blood. 2003;101:815-21. 
10. Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, et al. Role of 
intravitreal methotrexate in the management of primary central nervous system lymphoma with 
ocular involvement. Ophthalmology. 2002;109:1709-16. 
11. Patel DV, Horne A, House M, Reid IR, McGhee CN. The incidence of acute anterior uveitis 
after intravenous zoledronate. Ophthalmology. 2013;120:773-6. 
12. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A 
registry-based study. Arthritis Rheum. 2007;56:3248-52. 
13. Conrady CD, Larochelle M, Pecen P, Palestine A, Shakoor A, Singh A. Checkpoint inhibitor-
induced uveitis: a case series. Graefes Arch Clin Exp Ophthalmol. 2017. 
14. Eadie B, Etminan M, Mikelberg FS. Risk for Uveitis With Oral Moxifloxacin: A Comparative 
Safety Study. JAMA Ophthalmol. 2014. 
15. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, 
safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with 
refractory uveoretinitis. J Rheumatol. 2004;31:1362-8. 
16. Ramanan AV, Dick AD, Benton D, Compeyrot-Lacassagne S, Dawoud D, Hardwick B, et al. A 
randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis 
(SYCAMORE Trial). Trials. 2014;15:14. 
17. Brewerton DA, Caffrey M, Nicholls A, Walters D, James DC. Acute anterior uveitis and HL-A 
27. Lancet. 1973;302:994-6. 
18. Haroon M, O'Rourke M, Ramasamy P, Murphy CC, FitzGerald O. A novel evidence-based 
detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the 
DUET (Dublin Uveitis Evaluation Tool). Ann Rheum Dis. 2015;74:1990-5. 
19. Juanola X, Loza Santamaria E, Cordero-Coma M, Group SW. Description and Prevalence of 
Spondyloarthritis in Patients with Anterior Uveitis: The SENTINEL Interdisciplinary Collaborative 
Project. Ophthalmology. 2016;123:1632-6. 
20. Monnet D, Breban M, Hudry C, Dougados M, Brezin AP. Ophthalmic findings and frequency 
of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology. 
2004;111:802-9. 
21. Kaiser PK, Lowder CY, Sullivan P, Sanislo SR, Kosmorsky GS, Meziano MA, et al. Chest 
computerized tomography in the evaluation of uveitis in elderly women. Am J Ophthalmol. 
2002;133:499-505. 
22. Han YS, Rivera-Grana E, Salek S, Rosenbaum JT. Distinguishing Uveitis Secondary to 
Sarcoidosis From Idiopathic Disease: Cardiac Implications. JAMA Ophthalmol. 2018. 
23. Umazume A, Kezuka T, Okunuki Y, Ooshita M, Usui Y, Hirano M, et al. Prediction of severe 
cardiac involvement by fundus lesion in sarcoidosis. Jpn J Ophthalmol. 2014;58:81-5. 
24. Mandeville JT, Levinson RD, Holland GN. The tubulointerstitial nephritis and uveitis 
syndrome. Surv Ophthalmol. 2001;46:195-208. 
25. Mackensen F, Smith J, Rosenbaum JT. Enhanced recognition, treatment, and prognosis of 
tubulointerstitial nephritis and uveitis syndrome. Ophthalmology. 2007;114:995-9. 
26. Rosenbaum JT. Nibbling away at the diagnosis of idiopathic uveitis. JAMA Ophthalmol. 
2015;133:146-7. 
27. Jabs DA, Busingye J. Approach to the diagnosis of the uveitides. Am J Ophthalmol. 
2013;156:228-36. 
28. Rosenbaum JT, Wernick R. Selection and interpretation of laboratory tests for patients with 
uveitis. Int Ophthalmol Clin. 1990;30:238-43. 
29. Rosenbaum JT, Wernick R. The utility of routine screening of patients with uveitis for 
systemic lupus erythematosus or tuberculosis. A Bayesian analysis. Arch Ophthalmol. 
1990;108:1291-3. 
30. Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V, et al. Secukinumab 
in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. 
Ophthalmology. 2013;120:777-87. 
31. Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL, et al. Efficacy and safety of 
intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive 
therapy. Ophthalmology. 2015;122:939-48. 
32. Tugal-Tutkun IM, Kadayifcilar SM, Khairallah MM, Lee SCMP, Ozdal P, Ozyazgan Y, et al. 
Safety and Efficacy of Gevokizumab in Patients with Behcet's Disease Uveitis: Results of an 
Exploratory Phase 2 Study. Ocul Immunol Inflamm. 2017;25:62-70. 
33. Nguyen QD, Sadiq MA, Soliman MK, Agarwal A, Do DV, Sepah YJ. The Effect of Different 
Dosing Schedules of Intravitreal Sirolimus, a Mammalian Target of Rapamycin (mTOR) Inhibitor, in 
the Treatment of Non-Infectious Uveitis (An American Ophthalmological Society Thesis). Trans Am 
Ophthalmol Soc. 2016;114:T3. 
34. Miloslavsky EM, Naden RP, Bijlsma JW, Brogan PA, Brown ES, Brunetta P, et al. Development 
of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2016. 
35. Esterberg E, Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis 
specialists. J Ophthalmic Inflamm Infect. 2012;2:21-8. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
36. Lee RW, Greenwood R, Taylor H, Amer R, Biester S, Heissigerova J, et al. A randomized trial 
of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in 
noninfectious uveitis. Ophthalmology. 2012;119:1223-30. 
37. Nguyen QD, Hatef E, Kayen B, Macahilig CP, Ibrahim M, Wang J, et al. A cross-sectional study 
of the current treatment patterns in noninfectious uveitis among specialists in the United States. 
Ophthalmology. 2011;118:184-90. 
38. Writing Committee for the Multicenter Uveitis Steroid Treatment T, Follow-up Study 
Research G, Kempen JH, Altaweel MM, Holbrook JT, Sugar EA, et al. Association Between Long-
Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and 
Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis. JAMA. 
2017;317:1993-2005. 
39. Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in Patients 
with Active Noninfectious Uveitis. N Engl J Med. 2016;375:932-43. 
40. Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for 
prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by 
corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 
trial. Lancet. 2016;388:1183-92. 
41. Rosenbaum JT. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis 
associated with Behcet's disese. J Rheumatol. 2004;31:1241-3. 
42. Messenger W, Hildebrandt L, Mackensen F, Suhler E, Becker M, Rosenbaum JT. 
Characterisation of uveitis in association with multiple sclerosis. Br J Ophthalmol. 2015;99:205-9. 
43. Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, et al. 
Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 
2017;376:1637-46. 
44. Quartier P, Baptiste A, Despert V, Allain-Launay E, Kone-Paut I, Belot A, et al. ADJUVITE: a 
double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile 
idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2017. 
45. Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R, Jr., Brezin AP, Chee SP, et al. Guidance on 
Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals of 
Care for Uveitis (FOCUS) Initiative. Ophthalmology. 2018. 
46. Wakefield D, McCluskey P, Wildner G, Thurau S, Carr G, Chee SP, et al. Inflammatory eye 
disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and 
biologic therapy: Recommendations from an expert committee. Autoimmun Rev. 2017;16:213-22. 
47. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Bonilla G, Ruiz-Sancho D, et 
al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J 
Rheumatol. 2003;30:1277-9. 
48. Dougados M, Berenbaum F, Maetzel A, Amor B. Prevention of acute anterior uveitis 
associated with spondyloarthropathy induced by salazosulfapyridine. Rev Rhum. 1993;60:81-3. 
49. Lie E, Lindstrom U, Zverkova-Sandstrom T, Olsen IC, Forsblad-d'Elia H, Askling J, et al. 
Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing 
spondylitis: results from the Swedish biologics register. Ann Rheum Dis. 2017;76:1515-21. 
50. Trapani I, Banfi S, Simonelli F, Surace EM, Auricchio A. Gene therapy of inherited retinal 
degenerations: prospects and challenges. Hum Gene Ther. 2015;26:193-200. 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Figure legends: 
1. Anatomy of the eye. The uveal tract includes the iris, ciliary body, and choroid. It is 
shown in lavender. 
2A. Anterior uveitis is defined as inflammation of the iris and/or ciliary body. 
2B. Intermediate uveitis is diagnosed when inflammatory cells in the vitreous humor are the 
predominant finding. 
2C. Posterior uveitis is diagnosed if the retina and/or choroid are inflamed. 
2D. Panuveitis is diagnosed if inflammation is present in the anterior uvea, the vitreous humor, 
and the retina or choroid. It is also possible to have anterior and intermediate uveitis if the 
retina and choroid are not involved or intermediate and posterior uveitis if inflammation in the 
anterior chamber is minimal or non-existent. 
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Diagnosis Comments 
Adverse reaction to 
medication 
Drugs include TNF inhibitors, intravenous bisphosphonates, 
checkpoint inhibitors 
Ankylosing spondylitis Affects about 40% of patients with AS; usually unilateral, 
sudden onset, anterior, and recurrent 
Behcet’s syndrome Affects about 60 to 80% of patients with Behcet’s; usually 
bilateral, recurrent, often severe with associated retinal 
vasculitis 
Blau syndrome and other 
auto-inflammatory 
syndromes 
For Blau, uveitis is a common manifestation of an uncommon 
disease, usually bilateral with chorioretinitis; optic nerve edema 
or uveitis are also reported in NOMID or other auto-
inflammatory syndromes 
Crohn’s disease Uveitis and scleritis can be associated, often along with skin and 
joint disease; phenotype of uveitis resembles PsA-uveitis 
phenotype 
Juvenile idiopathic 
arthritis 
In the pauci-articular, early onset, ANA + subset, usually a 
bilateral, insidious onset, chronic anterior uveitis. Uveitis also 
associated with juvenile AS or juvenile onset PsA 
Kawasaki’s disease and 
rarely other forms of 
vasculitis 
Bilateral, mild anterior uveitis in association with conjunctivitis. 
PAN, GPA, LCV, or GCA very rarely cause uveitis. 
Lyme disease Rare but reported cause of uveitis. 
Psoriatic arthritis Affects about 7% of patients with PsA; can be bilateral, chronic, 
anterior and intermediate, and insidious in onset 
Reactive arthritis Conjunctivitis is classical eye manifestation but sudden onset, 
unilateral, anterior uveitis is well described 
Relapsing polychondritis Can cause iritis, episcleritis, or scleritis 
Rheumatic fever Very rarely associated with uveitis 
Sweet’s syndrome Rarely reported with uveitis 
Systemic lupus 
erythematosus 
Rarely causes uveitis or optic neuritis; often causes lacrimal 
gland disease; can cause cotton wool spots or choroidal 
vasculopathy 
Ulcerative colitis Uveitis or scleritis less common than with Crohn’s disease but 
clearly associated. 
Whipple’s disease Vitreous humor inflammation can be associated 
 
Table 1.  The differential diagnosis of uveitis in association with arthritis. Although this table includes 
rare causes of arthritis and uveitis such as Blau syndrome or Whipple’s disease, it does not include 
everything within the differential diagnosis. For example, tuberculosis could cause a uveitis and an 
arthritis simultaneously and some patients with arthritis of unknown cause also develop uveitis. 
Abbreviations: AS=ankylosing spondylitis; NOMID=neonatal onset multi-system inflammatory 
disease; PsA=psoriatic arthritis; ANA=anti-nuclear antibody; PAN=polyarteritis nodosa; 
GPA=granulomatosis with polyangiitis; LCV=leukocytoclastic vasculitis; GCA=giant cell arteritis. 
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Broad categories of 
disease associated with 
uveitis 
Comments 
Infections Includes viruses such as HSV, VZV, and CMV; syphilis, 
toxoplasmosis, and tuberculosis among other infections 
Masquerade syndromes Includes B cell lymphoma, leukemia, and retinal detachments 
Medication reactions See Table 1 
Ocular syndromes Includes birdshot retinochoroidopathy, pars planitis, acute 
multifocal placoid pigmentary epitheliopathy, and multifocal 
choroiditis with panuveitis 
Systemic immune-
mediated disease 
See Table 1; in addition includes multiple sclerosis, tubulo-
interstitial nephritis with uveitis, and Vogt-Koyanagi-Harada 
syndrome 
Trauma Penetrating trauma can cause sympathetic ophthalmia; surgical 
trauma as in cataract surgery usually causes some self-limited 
inflammation 
“idiopathic” Also called primary or undifferentiated uveitis; probably the 
most common diagnosis in a uveitis clinic 
 
 
Table 2. Abbreviations: HSV=herpes simplex virus; VZV=varicella virus; CMV=cytomegalovirus 
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Table 3.  A Glossary of Terms Often Used by A Uveitis Specialist 
Anterior uveitis: inflammation predominantly anterior to the lens of the eye. 
Band keratopathy: deposition of calcium in the corneal epithelium. It is a common finding in the 
uveitis associated with JIA. 
Cystoid macular edema: a common complication of uveitis that affects central vision and is often 
treated by a local injection of corticosteroid. 
Flare: the diffraction of the slit lamp beam caused by the increased protein in the anterior chamber 
that results when the blood aqueous barrier is disrupted as in anterior uveitis. 
Intermediate uveitis: inflammation predominantly in the vitreous humor. Neither the vitreous 
humor nor the anterior chamber technically are a part of the uveal tract, but leukocytes in either 
usually indicate a uveitis just as cells in the synovial fluid usually indicate a synovitis. 
Keratic precipitates: the concretions of cells adherent to the endothelium of the cornea as seen with 
a slit lamp examination. Large concretions are called “granulomatous” and are seen in such diseases 
as sarcoidosis, tuberculosis, and herpes zoster infection. 
Panuveitis: inflammation simultaneously in the anterior chamber, the vitreous humor and the retina 
and/or choroid. 
Posterior synechiae: the adherence of the iris to the lens. This is a non-specific finding which is 
nonetheless much more common in some forms of uveitis (such as that associated with HLA B27 or 
in sarcoidosis) than in others. 
Posterior uveitis: inflammation that involves the choroid and often adjacent structures such as the 
retina. 
Retinal vasculitis: an abnormality of retinal vessels such as increased vascular permeability. Retinal 
vasculitis is a common feature of many forms of uveitis and does not correlate well with the 
occurrence of a systemic vasculitis. 
SUN criteria: an acronym for the Standardization of Uveitis Nomenclature, an international 
consortium that helped to define terms related to uveitis. 
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Diagnosis Comment Lab Testing 
Behcet’s disease Typically a bilateral, recurrent, 
potentially blinding panuveitis 
associated with retinal 
vasculitis 
No definitive test; strictly a 
clinical diagnosis 
Birdshot retino-choroidopathy A chronic, bilateral 
intermediate and posterior 
uveitis very strongly associated 
with HLA A29 and frequently 
treated by chronic 
immunosuppression 
Almost all patients are HLA 
A29+ 
Blau syndrome A very rare, autosomal 
dominant form of uveitis 
associated with mutations in 
the nucleotide binding domain 
of NOD2, a gene which codes 
for an important component of 
the innate immune system 
which recognizes bacterial cell 
wall 
 
Genotyping identifies the 
mutations known to be 
associated with this syndrome 
HLA B27-related: Typically, a sudden onset, self-
limited (resolves within 3 
months), anterior, recurrent, 
unilateral uveitis. Most uveitis 
from any cause is anterior and 
50% of those with a sudden 
onset of anterior uveitis are 
HLA B27 positive, most of 
whom have some form of 
spondyloarthropathy. Usually 
can be managed by topical 
corticosteroids. 
 
HLA B27 typing; sacroiliac 
imaging to help diagnose 
associated spondyloarthritis 
Idiopathic The most common diagnosis in 
most series from a uveitis clinic. 
The term is used to mean a 
form of uveitis that does not fit 
a diagnostic niche. Other 
suggested terms include non-
classifiable, undifferentiated, or 
primary (as opposed to 
secondary to another condition 
such as ankylosing spondylitis). 
 
A diagnosis made when all 
other diagnoses have been 
excluded 
Juvenile idiopathic arthritis 
associated uveitis 
Characteristically a bilateral, 
insidious onset, chronic (lasting 
longer than 3 months), anterior 
uveitis, especially likely in 
patients with JIA who have a 
pauci-articular, early onset, 
A +ANA is supportive but it is 
neither sensitive nor specific 
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ANA positive form of arthritis 
 
Pars planitis A relatively common form of 
uveitis that usually begins 
insidiously and causes 
inflammation in the vitreous 
humor resulting in prominent 
floaters. (However, the majority 
of patients with floaters do not 
have pars planitis.) The disease 
is named for the pars plana, an 
anatomic area immediately 
posterior to the ciliary body and 
a site where leukocytic 
concretions are found in this 
disease. 
A clinical diagnosis based on 
the location of inflammation; 
occasionally associated with 
multiple sclerosis so a brain 
MRI is sometimes obtained. 
Primary intraocular lymphoma A very rare form of uveitis, 
usually occurring in individuals 
over 45, and presenting as 
bilateral cells in the vitreous 
humor, sometimes with 
subretinal infiltrates, and often 
in association with central 
nervous system lymphoma 
Definitive diagnosis is made by 
characterization of malignant 
cells in the vitreous humor or 
on retinal biopsy. 
Sarcoidosis A form of uveitis with 
“promiscuous” or highly varied 
presentations ranging from 
anterior uveitis to retinal 
vasculitis with or without 
chorioretinal lesions. Ocular 
inflammation and pulmonary 
disease are the two most 
common initial manifestations 
of sarcoidosis and it accounts 
for a relatively common 
systemic illness among patients 
in a uveitis clinic. 
 
Chest computed tomography is 
the most sensitive test. Biopsy 
is rarely required if symmetric 
hilar or mediastinal adenopathy 
is present. ACE, lysozyme, and 
interleukin-2 receptor have 
questionable specificity and 
limited sensitivity. 
Syphilis Late secondary or tertiary 
syphilis are in the differential 
diagnosis for any patient 
labelled as having “idiopathic” 
uveitis. 
FTA or comparable test is 
preferred. RPR can be negative 
in up to 40% of patients with 
uveitis secondary to syphilis. 
Tubulo-interstitial nephritis 
with uveitis 
A form of uveitis that is typically 
sudden onset, bilateral and 
mostly anterior with a variable 
amount of vitreous humor 
inflammation. The disease has 
an extremely strong association 
with HLA DRB1*0102.  Patients 
with TINU are typically 
Elevation of urine beta2 
microglobulin is a sensitive way 
to support the diagnosis. Renal 
biopsy is definitive but often 
not required. Serum blood urea 
nitrogen or serum creatinine 
have limited sensitivity. 
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systemically ill with fever, 
myalgias and arthralgias as well 
as a markedly elevated 
sedimentation rate. 
Tuberculosis A rare form of uveitis in the 
United States, but a very 
common form of uveitis in 
countries such as India or Saudi 
Arabia. Also a very difficult 
diagnosis to confirm as the 
organism is rarely cultured from 
the eye. The diagnosis should 
be considered if the patient has 
a risk factor for TB (such as 
being born outside the US or a 
history of incarceration) or if 
the illness does not respond to 
immunosuppression such as 
oral corticosteroids. 
 
Culture is the ideal 
confirmatory test, but it is often 
negative. PCR, when available, 
is a good alternative. 
Interferon gamma release 
assays and skin test responses 
are useful in confirming 
exposure to tuberculosis, but 
neither establishes if active 
infection is present. 
Vogt-Koyanagi-Harada 
syndrome 
An autoimmune form of uveitis 
with the triggering antigen 
putatively being tyrosinase. 
Patients are almost always 
either Asian, native American, 
or Spanish speaking. The uveitis 
is a bilateral, severe panuveitis 
with serous retinal elevation. 
Additional symptoms may 
include headache, 
meningismus, eight nerve 
abnormalities, and vitiligo. 
Fluorescein angiography and/or 
optical coherence tomography 
should show characteristic 
serous elevation of the retina. 
Whipple’s disease A rare but treatable cause of 
uveitis in association with 
arthritis. The presentation in 
the eye is generally cells in the 
vitreous humor. 
Identification of the causative 
organism, Tropheryma 
whippeli, in the vitreous humor 
or elsewhere 
Table 4.  Forms of Uveitis of Potential Special Interest to Rheumatologists. Abbreviations: 
ACE=angiotensin converting enzyme; FTA=fluorescent treponemal antibody; RPR=rapid plasma 
reagin; PCR=polymerase chain reaction. 
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